Analysts and investors alike will be keeping a close eye on the performance of Hercules Capital in its upcoming earnings disclosure. In that report, analysts expect Hercules Capital to post earnings of $0.51 per share. This would mark a year-over-year decline of 3.77%. Meanwhile, our latest consensus estimate is calling for revenue of $124.99 million, up 7.53% from the prior-year quarter. Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on thi ...

The yield is big, but as always, there are trade-offs to consider before diving in. Like dividends? A little outfit called Hercules Capital (HTGC -1.31%) dishes them out in a big way. Shares of this business development company boast a trailing dividend yield of a little over 8%, in fact, and that's based on just its ordinary quarterly payout. Adding its supplemental dividend to the mix cranks the trailing-12-month yield up to nearly 10%. Not bad. Before plowing into a new stake in this name based on nothin ...

Company Overview - Hercules Capital (HTGC) closed at $19.60, reflecting a decrease of -1.31% from the previous trading session, underperforming the S&P 500's gain of 0.23% [2] - The company is projected to report earnings per share (EPS) of $0.51, indicating a decline of 3.77% compared to the same quarter last year, while revenue is expected to reach $124.99 million, representing a growth of 7.53% year-over-year [6] Financial Performance - For the full year, Zacks Consensus Estimates forecast earnings of $2.06 per share and revenue of $503.7 million, showing changes of -0.96% and +9.34% respectively from the previous year [3] - Hercules Capital has gained 4.03% over the past month, outperforming the Finance sector's loss of 0.44% and the S&P 500's gain of 3.96% during the same period [9] Valuation Metrics - The company is currently trading at a Forward P/E ratio of 9.64, which is a premium compared to the industry average Forward P/E of 8.3 [4] Analyst Ratings - Hercules Capital holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.1% in the past month [7] - The Zacks Rank system has a strong track record, with 1 rated stocks generating an average annual return of +25% since 1988 [7] Industry Context - Hercules Capital operates within the Financial - SBIC & Commercial Industry, which has a Zacks Industry Rank of 145, placing it in the bottom 43% of over 250 industries [11]

Company Performance - Hercules Capital's shares experienced a loss of 0.45% over the previous month, underperforming the Finance sector's gain of 1.22% and the S&P 500's gain of 3.51% [1] - The latest trading session saw Hercules Capital ending at $19.79, reflecting a +0.1% adjustment from the previous day's close, outperforming the S&P 500's daily loss of 0.11% [6] Financial Estimates - The Zacks Consensus Estimates forecast earnings of $2.06 per share and revenue of $503.7 million for the entire year, indicating changes of -0.96% and +9.34%, respectively, compared to the previous year [2] - Analysts expect Hercules Capital to post earnings of $0.51 per share in the upcoming financial results, marking a year-over-year decline of 3.77%, while revenue is expected to be $124.99 million, showing a 7.53% increase compared to the year-ago quarter [7] Valuation Metrics - Hercules Capital's current Forward P/E ratio is 9.6, which is a premium compared to the average Forward P/E of 8.3 for its industry [4] Industry Ranking - The Financial - SBIC & Commercial Industry, which includes Hercules Capital, has a current Zacks Industry Rank of 89, placing it in the top 36% of over 250 industries [10] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [5] Analyst Estimates - Recent changes to analyst estimates for Hercules Capital reflect the latest short-term business trends, with positive revisions indicating optimism about the company's business outlook [8] - Hercules Capital currently holds a Zacks Rank of 3 (Hold), with the consensus EPS projection moving 0.1% higher in the past 30 days [9]

$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor) XOLREMDI, the first drug indicated in patients with WHIM syndrome, received U.S. FDA approval in April 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it has completed the sale of its Rare Pediatric Disease Priority Review ...

Meet the high-yield dividend payers that could raise your passive income stream.Investors eager to bulk up their passive income streams can do so without breaking the bank.At recent prices, Hercules Capital (HTGC 1.29%), Altria Group (MO -0.23%), and AT&T (T 0.83%) offer an average yield of 8.5% at recent prices. That's high enough to turn an initial investment of $5,890 into $500 of annual dividend income.There are plenty of dividend stocks with even higher yields right now. These three stand out because t ...

Klaus Vedfelt Hercules Capital, Inc. (NYSE:HTGC) reported robust quarterly earnings for its 1Q last week. The business development company once again covered its dividend with net investment income and achieved another quarter of record total gross fundings. The BDC's income trajectory looks solid, with Hercules Capital seeing 16% YoY total investment income growth, and the company maintained a very strong credit profile. Though Hercules Capital is richly valued, based on net asset value, I continue to see ...

Exhibit 99.1 Hercules Capital Reports First Quarter 2024 Financial Results Record Q1 2024 Total Gross Debt and Equity Commitments of $956.0 Million, an Increase of 81.7% Year-over-Year Record Q1 2024 Total Gross Fundings of $605.2 Million, an Increase of 27.1% Year-over-Year Q1 2024 Total Investment Income of $121.6 Million, an Increase of 15.7% Year-over-Year Q1 2024 Net Investment Income "NII" of $79.2 Million, or $0.50 per Share, an Increase of 20.9% Year-over-Year Q1 2024 NII Provides 125% Coverage of t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________________________________________ FORM 10-Q _________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 814-00702 _________________________________________________ HERCULE ...

SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody Provides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation Funding is additional to recent $75m Series B financing DUBLIN and OXFORD, England, April 30, 2024 /PRNewswire/ -- SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the ...